David A. Potter
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
David A. Potter has a total of 157 co-authors. Here are the top co-authors by number of shared publications:
- Douglas Yee
Masonic Cancer Center, University of Minnesota, Minneapolis, MN
14 shared publications - Adam L. Asare
19Quantum Leap Healthcare Collaborative, San Francisco, California
13 shared publications - Amy Jo Chien
University of California, San Francisco, San Francisco, USA
13 shared publications - Amy S. Clark
Division of Hematology and Oncology, Department of Medicine, University of Pennsylvania , Philadelphia, PA
13 shared publications - Amy Wilson
19Quantum Leap Healthcare Collaborative, San Francisco, California
13 shared publications - Andres Forero-Torres
University of Alabama at Birmingham, Birmingham, Alabama
13 shared publications
Latest Publications
- Open Access
- 19 December 2024
- Published by Elsevier in Current Problems in Cancer: Case Reports
- Vol. 17
A case of opsoclonus-myoclonus syndrome associated with breast cancer
- 19 December 2024
- Published by Elsevier in Current Problems in Cancer: Case Reports
- Vol. 17
Open AccessA case of opsoclonus-myoclonus syndrome associated with breast cancer
- Open Access
- 16 February 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S4 from Neoadjuvant Trebananib plus Paclitaxel-based Chemotherapy for Stage II/III Breast Cancer in the Adaptively Randomized I-SPY2 Trial—Efficacy and Biomarker Discovery
Trebananib vs Control pCR–Biomarker Associations
- 16 February 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S4 from Neoadjuvant Trebananib plus Paclitaxel-based Chemotherapy for Stage II/III Breast Cancer in the Adaptively Randomized I-SPY2 Trial—Efficacy and Biomarker Discovery
Trebananib vs Control pCR–Biomarker Associations
- Open Access
- 16 February 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Neoadjuvant Trebananib plus Paclitaxel-based Chemotherapy for Stage II/III Breast Cancer in the Adaptively Randomized I-SPY2 Trial—Efficacy and Biomarker Discovery
RPPA endpoints and genes/signatures involved in TIE2 signaling that were studied
- 16 February 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Neoadjuvant Trebananib plus Paclitaxel-based Chemotherapy for Stage II/III Breast Cancer in the Adaptively Randomized I-SPY2 Trial—Efficacy and Biomarker Discovery
RPPA endpoints and genes/signatures involved in TIE2 signaling that were studied
- Open Access
- 16 February 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Neoadjuvant Trebananib plus Paclitaxel-based Chemotherapy for Stage II/III Breast Cancer in the Adaptively Randomized I-SPY2 Trial—Efficacy and Biomarker Discovery
Representativeness of Study Participants
- 16 February 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Neoadjuvant Trebananib plus Paclitaxel-based Chemotherapy for Stage II/III Breast Cancer in the Adaptively Randomized I-SPY2 Trial—Efficacy and Biomarker Discovery
Representativeness of Study Participants
- Open Access
- 16 February 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Neoadjuvant Trebananib plus Paclitaxel-based Chemotherapy for Stage II/III Breast Cancer in the Adaptively Randomized I-SPY2 Trial—Efficacy and Biomarker Discovery
RPPA endpoints and genes/signatures involved in TIE2 signaling that were studied
- 16 February 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Neoadjuvant Trebananib plus Paclitaxel-based Chemotherapy for Stage II/III Breast Cancer in the Adaptively Randomized I-SPY2 Trial—Efficacy and Biomarker Discovery
RPPA endpoints and genes/signatures involved in TIE2 signaling that were studied
- Open Access
- 16 February 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S4 from Neoadjuvant Trebananib plus Paclitaxel-based Chemotherapy for Stage II/III Breast Cancer in the Adaptively Randomized I-SPY2 Trial—Efficacy and Biomarker Discovery
Trebananib vs Control pCR–Biomarker Associations
- 16 February 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S4 from Neoadjuvant Trebananib plus Paclitaxel-based Chemotherapy for Stage II/III Breast Cancer in the Adaptively Randomized I-SPY2 Trial—Efficacy and Biomarker Discovery
Trebananib vs Control pCR–Biomarker Associations
- Open Access
- 16 February 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Methods S1 from Neoadjuvant Trebananib plus Paclitaxel-based Chemotherapy for Stage II/III Breast Cancer in the Adaptively Randomized I-SPY2 Trial—Efficacy and Biomarker Discovery
Using Contemporary Controls and Adjusting for Time Trends in I-SPY2: The Time Machine
- 16 February 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Methods S1 from Neoadjuvant Trebananib plus Paclitaxel-based Chemotherapy for Stage II/III Breast Cancer in the Adaptively Randomized I-SPY2 Trial—Efficacy and Biomarker Discovery
Using Contemporary Controls and Adjusting for Time Trends in I-SPY2: The Time Machine
- Open Access
- 16 February 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Neoadjuvant Trebananib plus Paclitaxel-based Chemotherapy for Stage II/III Breast Cancer in the Adaptively Randomized I-SPY2 Trial—Efficacy and Biomarker Discovery
Kaplan-Meier survival plot of pCR vs. non-pCR in both trebananib and control arms
- 16 February 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Neoadjuvant Trebananib plus Paclitaxel-based Chemotherapy for Stage II/III Breast Cancer in the Adaptively Randomized I-SPY2 Trial—Efficacy and Biomarker Discovery
Kaplan-Meier survival plot of pCR vs. non-pCR in both trebananib and control arms
- Open Access
- 16 February 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Neoadjuvant Trebananib plus Paclitaxel-based Chemotherapy for Stage II/III Breast Cancer in the Adaptively Randomized I-SPY2 Trial—Efficacy and Biomarker Discovery
Representativeness of Study Participants
- 16 February 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Neoadjuvant Trebananib plus Paclitaxel-based Chemotherapy for Stage II/III Breast Cancer in the Adaptively Randomized I-SPY2 Trial—Efficacy and Biomarker Discovery
Representativeness of Study Participants